Peyronie's disease — the localized fibrotic disorder of the tunica albuginea causing penile curvature, pain, and erectile dysfunction through collagen plaque deposition — has transformed from a historically neglected men's health condition to an actively managed chronic disease, with the Peyronies Disease Treatment Market reflecting the shift from watchful waiting and invasive surgery to office-based enzymatic and mechanical therapies that address both the structural deformity and the psychological burden.

Collagenase clostridium histolyticum (CCH) as the non-surgical standard — the FDA approval of Xiaflex (Endo Pharmaceuticals) in 2013 for Peyronie's disease with palpable plaque and curvature greater than thirty degrees, establishing intralesional enzymatic plaque lysis as the first disease-modifying pharmacotherapy. The IMPRESS trials demonstrating mean curvature reduction of approximately seventeen to thirty-four percent and significant patient-reported improvement, with the injection-and-modeling protocol (breaking the plaque by manual penile modeling after injection) creating the office-based treatment paradigm that avoids the risks of penile shortening and erectile dysfunction associated with surgical plication or grafting.

Mechanical traction and combination strategies — the recognition that CCH alone produces modest curvature improvement, driving adoption of penile traction devices (RestoreX, developed at Mayo Clinic) used in conjunction with CCH or as standalone therapy. The RestoreX trials demonstrating additional curvature reduction when traction follows CCH injections, with the device also counteracting the penile shortening that concerns patients as much as the curvature itself. The daily traction protocol (thirty to sixty minutes) requiring patient compliance but offering the only non-surgical method to actually lengthen the shortened side of the tunica.

Surgical precision and patient selection — the continued role of surgical correction (Nesbit plication for curvature <60 degrees with adequate length; plaque incision/partial excision with grafting for severe curvature or hourglass deformity; penile prosthesis implantation for concurrent refractory erectile dysfunction) as the definitive solution when non-surgical therapies fail. The emphasis on penile duplex Doppler ultrasound for preoperative vascular assessment and 3D-printed models for surgical planning, ensuring that patients understand realistic outcomes including potential length loss with plication versus grafting complications.

Do you think the combination of collagenase and traction devices will eventually replace surgical correction as the first-line approach for all but the most severe Peyronie's cases, or will patient demand for rapid, single-procedure definitive correction maintain surgery's role?

What is collagenase clostridium histolyticum (CCH), and how does it treat Peyronie's disease? Mechanism: CCH (Xiaflex) is a purified bacterial collagenase mixture (AUX-I and AUX-II) that enzymatically degrades collagen types I and III — the primary structural proteins in Peyronie's plaques; injected directly into the plaque, it breaks down collagen cross-links, softening and reducing plaque volume. Administration: Up to four treatment cycles (two injections per cycle, separated by 24-72 hours); penile modeling performed by physician after second injection; patient continues modeling at home. Efficacy: IMPRESS trials — mean curvature reduction 34% (vs. 18% placebo); approximately 60% of patients achieve ≥25% improvement; plaque consistency softens; pain resolution common. Side effects: Penile ecchymosis (common), swelling, pain at injection site, corporal rupture (penile fracture risk — rare but serious, requiring surgical repair); contraindicated if plaque involves urethra. Cost: Approximately $3,000-4,000 per vial; two vials per cycle; four cycles typical; insurance coverage variable; total treatment cost $15,000-25,000+.

What are the surgical options for Peyronie's disease, and when are they indicated? Nesbit plication: For curvature <60 degrees with preserved erectile function and adequate penile length; non-diseased (longer) side of tunica is shortened with permanent sutures; simple, durable curvature correction; trade-off is penile shortening (typically 1-2 cm); lowest complication rate; most common surgical approach. Plaque incision/excision with grafting: For severe curvature (>60 degrees), hourglass deformity, or calcified plaques unresponsive to CCH; plaque is incised or partially excised and defect grafted with autologous vein, dermis, or synthetic materials (SIS, Tutoplast); maintains or restores length; higher risk of erectile dysfunction (20-30%) due to graft site veno-occlusive failure; requires preoperative vascular testing. Penile prosthesis implantation: For patients with concurrent severe erectile dysfunction unresponsive to PDE5 inhibitors; inflatable or malleable prosthesis placed with concurrent modeling or plaque manipulation; simultaneously addresses both ED and deformity; high satisfaction rates in appropriately selected patients. Timing: Surgery generally deferred until disease stable (12+ months from onset, 6+ months without progression) to avoid recurrence in active phase.

What causes Peyronie's disease, and who is at risk? Pathophysiology: Repeated microtrauma to erect penis during sexual intercourse (buckling injury) causes tunical bleeding and inflammation; abnormal wound healing with excess collagen deposition by fibroblasts/myofibroblasts; genetic predisposition (HLA-B7, HLA-B27 associations); altered TGF-β1 signaling and matrix metalloproteinase imbalance. Risk factors: Age 40-70 (peak 50s); Dupuytren's contracture (20-30% association); Ledderhose disease (plantar fibromatosis); diabetes; smoking; radical prostatectomy (neurovascular bundle injury); certain beta-blockers (controversial). Trauma: Acute penile fracture or repeated sexual microtrauma; penile injections for ED (rare). Genetics: Family history in approximately 2%; autosomal dominant pattern suggested in some families; association with Dupuytren's implies shared fibroproliferative diathesis. Natural history: Acute inflammatory phase (pain, evolving curvature, 6-18 months); stable/chronic phase (pain resolves, curvature stabilizes); spontaneous improvement in 10-15% (mild cases); progression in 30-50%; stable in remainder.

#PeyroniesDisease #MensHealth #Xiaflex #PenileCurvature #Urology #SexualHealth